Triomics

What are the products?

The vendor lists PRISM, Harmony, Symphony, visit preparation and registry curation as separate products. It says PRISM screens upcoming patients against every active trial nightly and gives coordinators a prioritized, cited worklist, with patient-to-trial, trial-to-patient and continuous tracking views. It re-evaluates when the chart changes, and matches arrive as in-basket messages or in the worklist.

Visit preparation is described as a snapshot of disease status, treatment timeline and biomarkers with a drafted pre-charting note. Registry curation covers NAACCR, SEER, COC and QOPI measures, with "a citation behind every field". The underlying model is named OncoLLM, which the vendor says reads notes, pathology, imaging, molecular reports and scanned faxes. Its architecture and providers are not described.

What does the vendor report?

Parts of the homepage show placeholder text, including lorem ipsum and a placeholder author name on a testimonial, and the PRISM page labels some of its metrics as placeholders. The vendor claims 120,000 charts read and more than 65,000 patients screened each month, ten or more NCI-designated customers, and that four of ten top US cancer centers trust it.

The vendor reports a 30% accrual lift and 40% more matches, shown at ASCO 2025, and an 80% visit reduction in a community oncology case study. None is peer reviewed. An unnamed customer quote on the site reads: "It has enabled us to pre-screen 100% of our patient visits against all our trials."

What is published, and where is it deployed?

The vendor points to a 2024 npj Digital Medicine paper, "PRISM: Patient Records Interpretation for Semantic clinical trial Matching system using large language models" (PMID 39468259), and cites about 95% matching accuracy. A 2026 paper in Surgery, "Understanding unrealized trial enrollments following patient-to-trial matching with large language models" (PMID 41318261), relates to a Central Surgical Association 2025 abstract the vendor lists.

Linked press names Memorial Sloan Kettering, Mount Sinai, Connecticut (via PR Newswire) and a Regenstrief case study. MSK's announcement calls Triomics "an oncology-focused generative artificial intelligence company".

Who sells it?

The footer reads "triomics inc.", with an address at 1 World Trade Center in New York that is not labeled as headquarters. Sarim Khan is co-founder and CEO and Sebastien Rhodes is VP of strategy and operations. Battery Ventures, Lightspeed, Nexus and Y Combinator are named as investors, with no amounts or dates.

The vendor says it is approved on the Epic App Marketplace, ingests HL7, FHIR, CCDA, PDF, TIFF and JPEG, and offers a synthetic-data sandbox where uploading a center's own data needs a BAA. The vendor makes no FDA claim, and no 510(k) record appears under Triomics.

There is no public price. The site offers a demo booking, an email address, a phone line, a 30-minute working session and the sandbox, with no trial terms.

The verdict

Visit preparation and registry curation are homepage descriptions, and whether they run beyond pilots is not stated. PRISM is the product with a dedicated page, a paper the vendor cites and a deployment announced by Memorial Sloan Kettering.